Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Ory

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
Cancers|January 9, 2021
The YAP/TEAD Axis as a New Therapeutic Target in Osteosarcoma: Effect of Verteporfin and CA3 on Primary Tumor GrowthSarah Morice, Mathilde Mullard, Regis Brion, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2015
Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma ProgressionBenjamin Ory, Marc Baud'huin, Franck Verrecchia, et al.
Nature Communications|March 21, 2014
Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycleFrançois Lamoureux, Marc Baud'huin, Lidia Rodriguez Calleja, et al.
European Journal of Human Genetics : EJHG|July 7, 2016
Protein-altering MYH3 variants are associated with a spectrum of phenotypes extending to spondylocarpotarsal synostosis syndromeRaphael Carapito, Alice Goldenberg, Nicodème Paul, et al.
International Journal of Cancer|June 26, 2014
BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcomaBérengère Gobin, Marc Baud' Huin, François Lamoureux, et al.
Frontiers in Cell and Developmental Biology|September 27, 2023
Ewing sarcoma from molecular biology to the clinicMaryne Dupuy, François Lamoureux, Mathilde Mullard, et al.
Oncotarget|March 24, 2016
Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1Camille Jacques, François Lamoureux, Marc Baud'huin, et al.
Scientific Reports|March 4, 2018
Identification of genomic differences among peripheral arterial beds in atherosclerotic and healthy arteriesMarja Steenman, Olivier Espitia, Blandine Maurel, et al.
Frontiers in Oncology|November 12, 2021
Involvement of the TGF-β Signaling Pathway in the Development of YAP-Driven Osteosarcoma Lung MetastasisSarah Morice, Geoffroy Danieau, Robel Tesfaye, et al.
Environmental Health Perspectives|June 12, 2023
Tracking Targets of Dynamic Super-Enhancers <i>in Vitro</i> to Better Characterize Osteoclastogenesis and to Evaluate the Effect of Diuron on the Maturation of Human Bone CellsRobel A Tesfaye, Melanie Lavaud, Céline Charrier, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Cancers|January 9, 2021
The YAP/TEAD Axis as a New Therapeutic Target in Osteosarcoma: Effect of Verteporfin and CA3 on Primary Tumor GrowthSarah Morice, Mathilde Mullard, Regis Brion, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2015
Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma ProgressionBenjamin Ory, Marc Baud'huin, Franck Verrecchia, et al.
Nature Communications|March 21, 2014
Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycleFrançois Lamoureux, Marc Baud'huin, Lidia Rodriguez Calleja, et al.
European Journal of Human Genetics : EJHG|July 7, 2016
Protein-altering MYH3 variants are associated with a spectrum of phenotypes extending to spondylocarpotarsal synostosis syndromeRaphael Carapito, Alice Goldenberg, Nicodème Paul, et al.
International Journal of Cancer|June 26, 2014
BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcomaBérengère Gobin, Marc Baud' Huin, François Lamoureux, et al.
Frontiers in Cell and Developmental Biology|September 27, 2023
Ewing sarcoma from molecular biology to the clinicMaryne Dupuy, François Lamoureux, Mathilde Mullard, et al.
Oncotarget|March 24, 2016
Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1Camille Jacques, François Lamoureux, Marc Baud'huin, et al.
Scientific Reports|March 4, 2018
Identification of genomic differences among peripheral arterial beds in atherosclerotic and healthy arteriesMarja Steenman, Olivier Espitia, Blandine Maurel, et al.
Frontiers in Oncology|November 12, 2021
Involvement of the TGF-β Signaling Pathway in the Development of YAP-Driven Osteosarcoma Lung MetastasisSarah Morice, Geoffroy Danieau, Robel Tesfaye, et al.
Environmental Health Perspectives|June 12, 2023
Tracking Targets of Dynamic Super-Enhancers <i>in Vitro</i> to Better Characterize Osteoclastogenesis and to Evaluate the Effect of Diuron on the Maturation of Human Bone CellsRobel A Tesfaye, Melanie Lavaud, Céline Charrier, et al.
Pageof 6